<DOC>
	<DOC>NCT01058707</DOC>
	<brief_summary>This is a Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects with Advanced Malignancies Followed by an Expansion in Subjects with renal cell carcinoma, endometrial cancer or urothelial cancer who have measurable disease</brief_summary>
	<brief_title>Dose Escalation Study of MLN0128 in Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Voluntary written consent Locally advanced or metastatic solid tumors with the exception of primary brain tumor, and have failed standard of care therapy Eastern Cooperative Oncology Group (ECOG) performance status 01 Ability to swallow oral medications For women of childbearing potential, negative serum or urine pregnancy test within 14 days prior to the first study drug administration and use of physicianapproved method of birth control from 30 days prior to 90 days following the last study drug administration Male subjects must be surgically sterile or must agree to use physicianapproved contraception during the study and for 90 days following the last study drug administration Clinical laboratory values as specified in the protocol Additionally, to be eligible for the Dose Expansion portion of the study: Subjects must have evidence of measurable disease per RECIST version 1.1 by radiographic techniques or magnetic resonance imaging Subjects must have a pathologic diagnosis of advanced or recurrent endometrial adenocarcinoma and must have failed at least 1 prior line of standard chemotherapy Subjects must have a pathologic diagnosis of advanced/metastatic urothelial cancer (carcinoma of the bladder, ureter, and/or renal pelvis) and must have failed at least 1 line of prior therapy in the metastatic/unresectable setting Subjects must have a pathologic diagnosis of advanced renal cell carcinoma (RCC), with histological or cytological confirmation of RCC and must have failed at least 1 prior line of antiVEGF therapy (including but not limited to sunitinib, and/or sorafenib, and/or bevacizumab and/or pazopanib, and/or axitinib) and must not have received prior therapy with a TORC1 inhibitor (such as temsirolimus or everolimus); or Subjects must have a pathologic diagnosis of advanced renal cell carcinoma (RCC) and must have progressed on treatment with a TORC1 inhibitor (such as temsirolimus or everolimus). Diagnosis of primary brain tumor Have received prior cancer or other investigational therapy within 2 weeks prior to the first administration of study drug Known impaired cardiac function or clinically significant cardiac disease Known treatment with systemic corticosteroid within one week prior to the first administration of study drug Diabetes mellitus HIV infection Known active cardiovascular disease condition as specified in protocol Failed to recover from the reversible effects of prior anticancer therapies Pregnancy (positive serum or urine pregnancy test) or breast feeding Malabsorption due to prior gastrointestinal (GI) surgery, GI disease Other clinically significant comorbidities Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria. Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Solid tumors, MLN0128, TORC1/2 inhibitors</keyword>
</DOC>